Cargando...
TARGETED THERAPIES: Afatinib—new therapy option for EGFR-mutant lung cancer
On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of pati...
Gardado en:
| Publicado en: | Nat Rev Clin Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4665630/ https://ncbi.nlm.nih.gov/pubmed/23959269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2013.154 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|